For the fifth year in a row, Centrient Pharmaceuticals* Receives 2024 Gold Sustainability Rating from EcoVadis
Centrient Pharmaceuticals, a key global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals, is proud to announce that for the fifth year in a row, it was awarded a Gold rating from EcoVadis. This is a testament to Centrient’s dedication to ESG principles and its continuous efforts to embed sustainability across all its business operations, reinforcing our leadership in the generics pharmaceutical sector.
The Gold rating ranks Centrient among the top 5% of all companies assessed by EcoVadis and in the top 4% of companies assessed in the manufacturing of basic pharmaceutical products and pharmaceutical preparations. The rating is fully aligned with our ESG Strategy 2021- 2030, supporting our targets around governance.
Centrient was evaluated under the themes of Environment, Labor and Human Rights, Ethics, and Sustainable Procurement, reflecting steady improvements across each category. Key highlights include:
- Receiving validation of our near-term climate targets for reducing absolute scope 1 and 2 emissions by 46.2% by 2031 and absolute reduction in scope 3 (purchased goods and services and fuel and energy-related activities) by 27.5% by 2031;
- Receiving independent third-party AMR certification from the British Standards Institute (BSI) for our APIs at our Santa Perpetua, Spain manufacturing site
Centrient’s Chief Executive Officer, Rex Clements, states “Receiving the Gold EcoVadis rating for the fifth year in a row is a testament to our robust ESG practices. Year over year, we strive to lead our sustainability efforts with transparency and integrity, as highlighted in our ESG report, so that we can continue to improve lives by manufacturing our medicines innovatively and sustainably.”
EcoVadis is one of the world’s most trusted providers of business sustainability ratings, providing detailed assessments of business’ environmental, social, and ethical performance. Based on leading standards, such as GRI, UNGC, and ISO 26000, the rating is supervised by an international scientific committee. EcoVadis ratings have been tested on over 100,000+ companies across 200+ industries and 175+ countries.
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing.
For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
(*) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.
